Medytox s legal win over Daewoong Pharmaceutical is expected to shake up the local botulinum toxin (BTX) market, as Medytox, Korea s first Botox developer, is also embroiled in a legal tussle with another competitor, Hugel in the United States, over the BTX strain used to manufacture the cosmetics treatment, according to the companies, Monday. On Friday, the Seoul District Court ruled that Daewoong s BTX products were developed by stealing Medytox s BTX strains and manufacturing processes.